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Multi-Site Coronary Vein Sampling Study on Cardiac Troponin T
Degradation in Non–ST-Segment–Elevation Myocardial Infarction:
Toward a More Speciﬁc Cardiac Troponin T Assay
Sander A. J. Damen, MD;* Wim H. M. Vroemen, MSc;* Marc A. Brouwer, MD, PhD; Stephanie T. P. Mezger, MSc; Harry Suryapranata, MD,
PhD; Niels van Royen, MD, PhD; Otto Bekers, PhD; Steven J. R. Meex, PhD; Will K. W. H. Wodzig, PhD; Freek W. A. Verheugt, MD, PhD;
Douwe de Boer, PhD; G. Etienne Cramer, MD; Alma M. A. Mingels, PhD
Background-—Cardiac troponin T (cTnT) is seen in many other conditions besides myocardial infarction, and recent studies
demonstrated distinct forms of cTnT. At present, the in vivo formation of these different cTnT forms is incompletely understood. We
therefore performed a study on the composition of cTnT during the course of myocardial infarction, including coronary venous
system sampling, close to its site of release.
Methods and Results-—Baseline samples were obtained from multiple coronary venous system locations, and a peripheral artery
and vein in 71 non–ST-segment–elevation myocardial infarction patients. Additionally, peripheral blood was drawn at 6- and 12-
hours postcatheterization. cTnT concentrations were measured using the high-sensitivity-cTnT immunoassay. The cTnT
composition was determined via gel ﬁltration chromatography and Western blotting in an early and late presenting patient.
High-sensitivity -cTnT concentrations were 28% higher in the coronary venous system than peripherally (n=71, P<0.001). Coronary
venous system samples demonstrated cTn T-I-C complex, free intact cTnT, and 29 kDa and 15 to 18 kDa cTnT fragments, all in
higher concentrations than in simultaneously obtained peripheral samples. While cTn T-I-C complex proportionally decreased, and
disappeared over time, 15 to 18 kDa cTnT fragments increased. Moreover, cTn T-I-C complex was more prominent in the early than
in the late presenting patient.
Conclusions-—This explorative study in non–ST-segment–elevation myocardial infarction shows that cTnT is released from
cardiomyocytes as a combination of cTn T-I-C complex, free intact cTnT, and multiple cTnT fragments indicating intracellular cTnT
degradation. Over time, the cTn T-I-C complex disappeared because of in vivo degradation. These insights might serve as a
stepping stone toward a high-sensitivity-cTnT immunoassay more speciﬁc for myocardial infarction. ( J Am Heart Assoc. 2019;8:
e012602. DOI: 10.1161/JAHA.119.012602.)
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T he introduction of high-sensitivity cardiac troponin(hs-cTn) immunoassays to diagnose myocardial infarc-
tion (MI) has led to frequent reporting of elevated cTn
levels in conditions other than MI.1–5 This limitation in
speciﬁcity complicates clinical decision making on a daily
basis, and new strategies to overcome this issue are highly
warranted.6
For cardiac troponin T (cTnT), degradation of its intact
form into multiple cTnT fragments was observed in patients
who have acute MI.7–9 Interestingly, in other conditions
associated with cTnT elevations (eg, end-stage renal
disease), only the smallest cTnT forms were present.10,11
The current clinical high-sensitivity (hs)-cTnT immunoassay
detects all these circulating cTnT forms. As suggested by
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others, a novel assay that would speciﬁcally target distinct
cTnT forms might increase diagnostic speciﬁcity for MI.12–14
Before this will become feasible, however, more basic
knowledge on the origin and formation of troponin forms
seems indispensable.
Until now, the majority of studies on cTnT degradation in
MI patients were conducted on serum samples.7,8,11,15–17 This
is of particular importance because thrombin is generated
during serum collection and thrombin has repeatedly been
shown to cause cTnT degradation.18,19 Some have therefore
postulated that cTnT degradation is merely a pre-analytical
effect instead of an in vivo degradation pathway.18 Alterna-
tively, as cTnT degradation in MI patients follows a time-
dependent pattern, it has been suggested that in vivo
processes, at least in part, also contribute to cTnT degrada-
tion.7,15,16,20 In addition, in vitro studies have shown that
intracellular proteases are also involved in the degradation of
cTnT, but supportive in vivo evidence is lacking.21–24
In view of the above, it remains to be determined at which
site(s) cTnT degradation actually occurs. The goal of this study
was to investigate the cTnT composition(s) close to the site of
release and during the course of MI. This was studied through
multisite sampling both in the coronary venous system (CVS)
as well as in the peripheral circulation in patients with non–
ST-segment–elevation myocardial infraction (NSTEMI) using
gel ﬁltration chromatography (GFC) and Western blotting
(WB). To assess the impact of pre-analytical degradation, all
analyses were performed in both lithium-heparinized (LH)
plasma and serum samples. These insights might serve as a
stepping stone for the development of a novel hs-cTnT assay
more speciﬁc for MI.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Patient Population
The TRAMICI study (Transcardiac Assessment of Myocardial
Injury and Coronary Inﬂammation; see online supplemental
Data S1 for description of the inclusion and exclusion criteria,
and study procedures) was used to select eligible patients for
the present study. The goal of the TRAMICI study was central,
peripheral, and transcardiac assessment of cardiac biomarkers
and inﬂammatory parameters in non–ST-segment–elevation
acute coronary syndromes. The TRAMICI cohort included 71
patients with NSTEMI undergoing clinically indicated cardiac
catheterization. Patients were treated according to the acute
coronary syndrome guidelines, including treatment with aspirin
and a P2Y12-inhibitor. During coronary angiography, every
patient was anticoagulated with heparin.
With regard to patient selection for cTnT composition
analyses, the following criteria were speciﬁed: (1) deﬁnite
culprit lesion in the left anterior descending coronary artery
(coronary artery that delivers blood to the anterior wall); (2)
availability of all samples in accordance with the TRAMICI
protocol; and (3) a minimum hs-cTnT concentration of
400 ng/L (sensitivity threshold of our laboratory setup, see
below) in all CVS and peripheral samples. Of the patients who
met these criteria, we selected the patient with the shortest
and longest interval between symptom onset and study
procedures. The TRAMICI protocol was approved by the local
ethical committee (2004-186) of the Radboud University
Medical Center (Nijmegen, The Netherlands). After obtaining
oral informed consent before the procedure, participants
provided written informed consent. Study procedures were in
accordance with the Declaration of Helsinki.
Sample Collection
Our extensive blood sampling protocol is described in the
supplemental material. In short, access to the CVS was gained
after identiﬁcation of a culprit artery by the attending
interventional cardiologist. Blood samples were obtained from
the great cardiac vein, the coronary sinus at the site of the
most proximal posterolateral vein, and at the ostium of the
middle cardiac vein (Figure S1). Hereafter, samples were
obtained from the peripheral venous and arterial sheaths.
Subsequently, peripheral venous samples were obtained by
venipuncture from the antecubital vein 6 and 12 hours after
cardiac catheterization. All blood samples were collected in
LH plasma and serum tubes, centrifuged, divided over multiple
aliquots preventing freeze–thaw cycles, and stored at 80°C
until further analysis.
Clinical Perspective
What Is New?
• Cardiac troponin T (cTnT) is released from the injured
myocardium in multiple forms (ie, cardiac troponin T-I-C
complex, free intact cTnT subunit, and several cTnT
fragments).
• cTnT is subject to in vivo degradation, which may already
take place within the cardiomyocyte.
• The cTnT composition is dependent on the interval that
passed since the onset of symptoms.
What Are the Clinical Implications?
• A high-sensitivity cTnT immunoassay solely targeting cTnT
forms ≥29 kDa may discriminate cTnT release in the setting
of a myocardial infarction from cTnT release in other
(patho)physiologies.
• The proportion of ternary cardiac troponin T-I-C complex
might hint toward the age of the myocardial infarction.
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Laboratory Techniques
Details on the different laboratory techniques used are
presented in the online supplement (Data S1) and described
in brief as follows.
Biochemical assessment
hs-cTnT concentrations were measured with the hs-cTnT
immunoassay (Roche Diagnostics, Basel, Switzerland). This
assay utilizes 2 monoclonal antibodies: M11.7 and M7. These
epitopes are present in all cTnT forms (ie, cTn T-I-C complex,
free intact 40 kDa cTnT, 29 kDa cTnT, and 15 to 18 kDa cTnT
fragments). In addition, creatinine levels were assessed
(CREP2; Roche Diagnostics). Assay characteristics were as
provided by the manufacturer and measurements were
performed on the e601 module of the COBAS 6000 analyzer
series and c702 module of the COBAS 8000 analyzer series
(Roche Diagnostics). The estimated glomerular ﬁltration rate
was calculated according to the Chronic Kidney Disease
Epidemiology Collaboration Formula (CKD-EPI).25
Gel ﬁltration chromatography
GFC was used to separate cTn T-I-C complex and free cTnT
forms based on size exclusion. Our GFC laboratory setup is
currently the most sensitive technology available to study the
cTnT composition and has already been validated for cTn T-I-C
complex and cTnT form separation in serum.10 A schematic
illustration of a GFC elution proﬁle and the expected
corresponding cTnT forms are depicted in Figure S2. To
validate potential blood matrix effects, puriﬁed human ternary
cTn T-I-C complex (#8T62; HyTest, Turku, Finland) and free
intact 40 kDa cTnT (#8T13; HyTest) standards were added to
GFC running buffer and hs-cTnT-negative (<3 ng/L) LH
plasma and serum from a pool of healthy individuals in a
concentration comparable to the 2 selected NSTEMI patients
for elaborate cTn T-I-C complex and cTnT composition
analyses.
For each sample loaded on the GFC column (0.25 mL),
either cTnT standard or patient sample, 83 fractions of 1 mL
were collected and analyzed for hs-cTnT concentration with
the hs-cTnT immunoassay.
Western blotting
To extend on the GFC data and further characterize the cTnT
composition, immunoprecipitation on both LH plasma and
serum samples was followed by Western blotting (WB)
analysis. To increase the discriminatory value of the GFC
technique with regard to cTnT form differentiation, WB
analysis was used to determine the exact cTnT composition
of the eluted GFC peaks.
The anti-cTnT monoclonal antibodies used for immunopre-
cipitation (M11.7) and WB (M7) were identical to those used
in the commercially available hs-cTnT immunoassay (kindly
provided by Roche Diagnostics). In contrast to GFC, it should
be noted that the cTn T-I-C complex cannot be analyzed by
WB because of the presence of the detergent sodium dodecyl
sulfate, which disintegrates the cTn T-I-C complex into the
different free intact cTn subunits. Therefore, GFC and WB are
considered complementary techniques.
Statistical Analysis
Results are presented as median (interquartile range) or
meanSD depending on Gaussian distribution. The Wilcoxon
signed-rank test was used to compare paired non-Gaussian
distributed hs-cTnT concentrations of the 3 CVS samples (ie,
great cardiac vein, posterolateral vein, and middle cardiac vein)
with the baseline peripheral arterial sample. To account for
multiple testing, the conservative Bonferroni correction was
applied to reduce the chance of type 1 errors (aBonfer-
roni=0.017). Hence, a P<0.017 was considered statistically
signiﬁcant. Comparison of the peripheral arterial and venous
sample was performed with the Wilcoxon signed-rank test.
Additionally, hs-cTnT concentration differences over time were
evaluated with the Friedman test followed by post hocWilcoxon
signed-rank test for pairwise comparisons. For these analyses,
a P<0.05 was considered statistically signiﬁcant. All statistical
analyses were performed using GraphPad Prism (version 5.04;
GraphPad Software, Inc., San Diego, CA).
For the GFC analysis, the hs-cTnT concentration of each
fraction was plotted on the y-axis of the graph, and on the x-
axis the 83 eluted fractions. To account for analytical noise,
we determined the mean hs-cTnT concentration of the
fractions between 0 and 15 mL and 64 to 83 mL, which are
exterior to the GFC elution peaks representing the cTnT
forms. This mean noise hs-cTnT concentration was subtracted
from the hs-cTnT concentration measured in the respective
fractions of each cTnT peak. After this noise correction, the
surface of each individual peak was calculated and expressed
relative (%) to the total surface of all observed cTnT peaks.
Results
Patient Characteristics
Baseline characteristics of the entire cohort of 71 NSTEMI
patients are depicted in Table. Mean age was 6512 years
and 68% were male. Cardiac catheterization was successfully
completed for all patients with a median (interquartile range)
time from symptom onset to cardiac catheterization of 1559
(1183–2167) minutes. The time between symptom onset and
cardiac catheterization was 461 and 1354 minutes for
patients 1 and 2, respectively. Patient 1 had a 95% stenosis
in segment 10 identiﬁed as the culprit lesion; for patient 2
the culprit lesion was an 80% stenosis in segment 7
(Figure S3).
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Highest hs-cTnT Concentrations in the CVS
In the entire cohort (n=71), the median hs-cTnT concentration
in the CVS was 230 (111–547) ng/L and signiﬁcantly higher
as compared with the peripheral artery sample with a median
hs-cTnT concentration of 180 (95–369) ng/L (28%, P<0.001)
(Figure 1). Median peripheral venous hs-cTnT concentrations
changed signiﬁcantly over time (Friedman P=0.002), which
was ascribed to an increase in concentration between
baseline and 6 hours postprocedure (P=0.004, Figure 1).
Also for the 2 selected patients, the highest hs-cTnT
concentrations were measured in the CVS. Between baseline
and 6 hours postprocedure, patient 1 showed an increase in
hs-cTnT from 474 to 1177 ng/L and patient 2 showed a
decrease from 1498 to 1214 ng/L. In line with the analytical
validation article, no hs-cTnT concentration differences
between serum and LH plasma were detected (R=0.995,
Figure S4).5
Validation of GFC Elution Proﬁles for cTnT
Standards
GFC elution proﬁles of the validation experiments using cTn
standards are depicted in Figure 2.
GFC buffer
The addition of cTn T-I-C complex and free intact 40 kDa cTnT
standards to the GFC buffer resulted in the detection of cTnT
peaks in theGFCelutionproﬁlesat21and30 mL(Figure 2A)and
29 mL (Figure 2B), respectively. WB characterization revealed
that cTnT in both standards consisted of intact 40 kDa cTnT
(100%, Figure 3). Therefore, the peak at 21 mL in Figure 2A is
assigned to cTn T-I-C complex, and the peak at 30 mL in
Figure 2A and 29 mL in Figure 2B to free intact 40 kDa cTnT.
LH plasma
Addition of cTn T-I-C complex and free intact 40 kDa cTnT
standards to LHplasma resulted in cTnTpeaks in theGFCelution
proﬁles at 21 and 32 mL (Figure 2C) and 29 mL (Figure 2D),
respectively. WB analysis revealed that cTnT in both standards
consisted of free intact 40 kDa cTnT (100%, Figure 3). Again, the
21 mL peak in Figure 2C corroborates with cTn T-I-C complex,
and the 32 and 29 mL peak (Figures 2C and 2D) with free intact
40 kDa cTnT. In contrast to the 2 peaks observed in Figure 2A,
the second peak in Figure 2C is larger than the ﬁrst, suggesting
more elaborate turnover of cTn T-I-C complex to free intact
40 kDa cTnT in LH plasma as compared with the GFC buffer.
Serum
Addition of cTn T-I-C complex and free intact 40 kDa cTnT
standards to serum resulted in cTnT peaks in the GFC proﬁles
at 30 and 44 mL (Figure 2E) and at 30 and 41 mL (Figure 2F),
respectively. WB analysis of the cTn T-I-C complex standard
illustrated presence of free intact 40 kDa cTnT (29%), 29 kDa
cTnT (60%), and 15 to 18 kDa cTnT (11%) fragments (Figure 3).
WB analysis of the free intact 40 kDa cTnT standard revealed
exclusive presence of cTnT fragments; 29 kDa cTnT (49%) and
15 to 18 kDa cTnT (51%) fragments (Figure 3).
As expected, in the GFC elution proﬁles of hs-cTnT-
negative LH plasma and serum, no cTnT peaks were identiﬁed
(Figures 2G and 2H).
From these validation experiments the following could be
concluded: (1) the 21 mL peak was assigned to cTn T-I-C
complex; (2) the 29 to 32 mL peak was assigned to free intact
40 kDa cTnT and/or 29 kDa cTnT fragments; and (3) the 41 to
44 mL peak was assigned to 15 to 18 kDa cTnT fragments
(Figure S2).
In Vitro Disintegration of cTn T-I-C Complex and
Degradation of cTnT in Serum
To determine the effect of the blood matrix, we compared
GFC proﬁles (Figure 4 and Figures S5 and S6) between
simultaneously obtained LH plasma and serum samples of the
2 selected patients.
In the CVS and peripheral baseline (T0) samples of both
patients, we observed 3 peaks in LH plasma, and only 2
Table. Baseline Characteristics of the Total Population (n=71)
and the 2 Selected Patients for cTnT Composition Analysis
Total Population (n=71) Patient 1 Patient 2
Sex, male 68% Male Male
Age, y 6512 61 53
BMI, kg/m2 26.1 (24.2–29.4) 30.8 30.7
Medical history
History of MI 23% No No
History of PCI/CABG 8% No No
History of stroke 6% No No
History of DM 11% No No
Blood pressure, mm Hg
Systolic 14431 135 115
Diastolic 7818 89 65
Heart rate, per min 7219 100 80
Hypercholesterolemia, % 37% Yes No
Current smoking, % 45% No No
Creatinine, lmol/L 83 (69–95) 69 88
eGFR per CKD-EPIcreat,
mL/min per 1.73 m2
82 (63–94) 98 87
BMI indicates body mass index; CABG, coronary artery bypass graft; CKD-EPI, chronic
kidney disease-epidemiology collaboration equation; DM, diabetes mellitus; eGFR,
estimated glomerular ﬁltration rate; MI, myocardial infarction; PCI, percutaneous
coronary intervention.
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peaks in the corresponding serum samples (Figures S5 and S6).
As compared with LH plasma, in serum there was no 20 to 22 mL
peak, which indicated absence of cTn T-I-C complex. In addition, all
observed 45 to 47 mL peaks were greater in serum than in LH
plasma, indicating a higher proportion of 15 to 18 kDa cTnT
fragments in serum (67–100%) as compared with LH plasma
(41–75%) (Figure 4). Finally, GFC analyses of the V-T12 sample of
both patients showed 2 peaks for the LH plasma sample at 31
and 45 to 46 mL, and only 1 peak for the corresponding
serum sample at 46 mL (Figures S5G and S5N; S6G and
S6M). These data indicate total absence of free intact 40 and
29 kDa cTnT fragments in serum.
WB analysis of the baseline (T0) LH plasma samples
primarily revealed the presence of free intact 40 kDa cTnT,
but 29 kDa and 15 to 18 kDa cTnT fragments were also
present (Figure 5). In serum we exclusively observed 29 kDa
and 15 to 18 kDa cTnT fragments (Figure 5). In addition to a
clear presence of 15 to 18 kDa cTnT fragments on WB
analysis of the V-T12 samples, there was also evidence of
29 kDa cTnT in both patients at T12 (Figure 5).
Hence, comparing simultaneously collected LH plasma and
serum samples revealed in vitro induced disintegration of the
cTn T-I-C complex and cTnT degradation in serum.
cTn T-I-C Complex Disintegration and cTnT
Degradation Occurs In Vivo
In order to investigate potential in vivo processes contributing
to cTn T-I-C complex disintegration and cTnT degradation, we
evaluated the cTnT composition in LH plasma over time and
between the early presenting patient 1 and late presenting
patient 2. In addition, we compared the observed cTnT forms
with the validation experiments.
GFC analyses showed that the proportion of cTn T-I-C
complex decreased over time in peripheral venous LH plasma
samples in patient 1 from 41% at V-T0 to 0% at V-T12 and
patient 2 from 2% at V-T0 to 0% at V-T6 (Figure 4). Simulta-
neously, the proportion of 15 to 18 kDa cTnT fragments
increased between V-T0 and V-T12 from 41% to 68% for patient
1 and from 56% to 75% for patient 2 (Figure 4). Additionally,
cTnT composition comparison between patient 1 and 2
revealed higher proportions of the larger cTnT forms (cTn
complex, free intact 40 and 29 kDa cTnT fragments) in patient
1 for all CVS and peripheral samples.
As depicted in Figure 5 using WB, detection of 29 kDa and
15 to 18 kDa cTnT fragments in LH plasma samples at T0 of
both our patients provides evidence of in vivo degradation. As
Figure 1. Median (box) and interquartile range (whiskers) hs-cTnT concentrations (ng/L) of the entire
cohort at the different coronary venous system (CVS) and peripheral sampling sites. *P<0.05; **P<0.001;
A-T0 indicates peripheral artery sample at baseline; GCV, great cardiac vein sample; hs-cTnT, high-
sensitivity cardiac troponin T; MCV, coronary sinus sample at the ostium of the middle cardiac vein; NS, not
signiﬁcant; PLV, coronary sinus sample near the proximal posterolateral vein; V-T0, peripheral vein sample
at baseline; V-T12, peripheral vein sample 12 hours postprocedure; V-T6, peripheral vein sample 6 hours
postprocedure.
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already shown in our validation experiments, in vitro degra-
dation of free intact 40 kDa cTnT to smaller 29 kDa and 15 to
18 kDa cTnT fragments did not occur in LH plasma.
cTn T-I-C Complex Disintegration and cTnT
Degradation Close to the Myocardium
To investigate potential in vivo cTn T-I-C complex disintegra-
tion and cTnT degradation within the heart, we compared the
cTnT composition in samples obtained in close vicinity of the
injured myocardium (ie, the CVS) with simultaneously
obtained peripheral samples.
On GFC analyses, the absolute concentrations of all cTnT
forms were higher within the CVS as compared with the
peripheral arterial samples (Figure 4 and Figures S5A through
S5D and S6A through S6D), which agrees with cardiac release
of each cTnT form. The relative contribution of each separate
cTnT peak to the total observed cTnT that eluted from the GFC
column remained constant among the 3 CVS sampling sites
(Figure 4 and Figures S5A through S5C and S6A through
S6C). The maximum variation within the CVS between the 3
different peaks were 3%, 6%, and 8% for patient 1 and 3%, 2%,
and 2% for patient 2 (Figure 4).
Thus, the identical cTnT composition in all CVS and baseline
peripheral samples, but higher hs-cTnT concentrations mea-
sured in the GFC elution proﬁles of the CVS samples, indicates
release of all cTnT forms (cTn T-I-C complex, free intact 40 kDa
cTnT and cTnT fragments) from the myocardium.
Figure 2. Gel ﬁltration chromatography (GFC) analyses of cTnT standards (cTn T-I-C complex and free intact 40 kDa cTnT) in multiple
matrices. cTn T-I-C complex in (A) GFC buffer, (C) lithium-heparinized (LH) plasma, and (E) serum. Free intact 40 kDa cTnT in (B) GFC buffer, (D)
LH plasma, and (F) serum. cTnT-negative (G) LH plasma and (H) serum. The hs-cTnT concentration (ng/L) before GFC fractionation is displayed
in the upper right corner of each panel. Also, the retention volume (mL) with highest hs-cTnT concentration per peak is displayed. hs-cTnT
indicates high-sensitivity cardiac troponin T.
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Discussion
In search of improved cTnT assay speciﬁcity, detailed
knowledge of the in vivo molecular appearance of cTnT in
the setting of ischemic heart disease is fundamentally
important. The unique design of the present study enabled
us to determine the in vivo cTnT composition in close vicinity
of the infarcted myocardium using multisite blood sampling in
the CVS and compare it with the peripheral circulation in
NSTEMI patients. We report 4 major ﬁndings:
First, to the best of our knowledge, this is the ﬁrst study
investigating hs-cTnT concentrations at multiple sites within
the CVS. We showed 30% higher hs-cTnT concentrations in
the CVS samples compared with baseline peripheral samples,
which is in line with active cTnT release from the injured
myocardial cells. This concentration gradient was also noticed
by Turer et al, who demonstrated hs-cTnT elevation through
coronary sinus sampling after pacing-induced stress in stable
angina patients.26
Second, we found matrix-induced in vitro cTn T-I-C complex
disintegration andmore elaborate cTnT degradation in serum as
compared with LH plasma. As illustrated by our GFC validation
analyses, the cTn T-I-C complex was no longer demonstrable in
serum, whereas in LH plasma little cTn T-I-C complex was
observed. This difference between serum and LH plasma was
also observed in the 2 patients, in whom cTn T-I-C complex was
fully absent in serum. In addition, GFC data of the 2 patients
showed that cTnT in serum was primarily present as 15 to
18 kDa fragments in all CVS and peripheral samples with
proportions greater than observed in LH plasma. These data are
in alignment with Katrukha et al, who predominantly detected
free intact 40 kDa cTnT in LH plasma of acuteMI patients, while
in simultaneously collected serum samples exclusively cTnT
fragments were observed.18 This pre-analytical effect has been
allocated to abundantly generated thrombin during serum
production,18–20,27 and we conclude that the cTnT composition
in LH plasma samples is a better representation of the in vivo
situation in these patients.
Third, we also found evidence of in vivo processes that
contributed to cTn T-I-C complex disintegration and cTnT
degradation. As was observed in LH plasma samples of the 2
patients, there was a time-dependent degradation pattern. Over
time a change in cTnT composition occurred with a decreasing
magnitudeof cTn T-I-C complex and increasing proportions of 15
to 18 kDa cTnT fragments. Moreover, the difference between
the early and late presenting patient appeared to be in
accordance with this. In the early presenting patient, the
proportion of cTn T-I-C complex was still 25% (peripheral artery),
whereas in the late presenting patient cTn T-I-C complex was
almost absent (4%, peripheral artery). All these ﬁndings were
observed using LH plasma as blood matrix. Importantly, the
change in cTnT composition over time corroborates with
previous observations in peripheral serum samples of MI
patients.7,17,28 Interestingly, ourWB data were also conﬁrmative
Figure 3. Immunoprecipitation followed by Western blot analysis of cTnT standards (cTn T-I-C complex and free intact 40 kDa cTnT) added to
gel ﬁltration chromatography (GFC) buffer, cTnT negative lithium-heparinized (LH) plasma and serum. hs-cTnT indicates high-sensitivity cardiac
troponin T; M, protein standard marker; N, negative control; P, cTnT positive control.
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of in vivo degradation. As we showed in our LH plasma validation
experiments, the cTnT thatwas present in the standard solutions
was exclusively free intact 40 kDa cTnT. Therefore, the
presence of the 29 kDa and 15 to 18 kDa cTnT fragments in
the 2 patients is also proof of in vivo cTnT degradation.
Fourth, we provide evidence of each separate cTnT form (ie,
cTn T-I-C complex, free intact 40 kDa cTnT, 29 kDa, and 15 to
18 kDa cTnT fragments), detected in the CVS, to be released
from the injured myocardium. For each cTnT form, the absolute
hs-cTnT concentration was higher in the CVS as compared with
baseline peripheral measurements. This is an important ﬁrst-
time observation because our ﬁndings of in vivo cTnT
degradation could be interpreted as the natural course of
peripheral protein degradation. This evidence of release into
the CVS suggests that degradation occurred in vivo inside the
ischemic cardiomyocytes. In this regard, intracellular l-calpain
and caspase-3 were suggested as contributors to intracellular
cTnT degradation and were shown to have proteolytic capacity
on the N-terminal region of cTnT.21–24 Alternatively, despite the
observed transcardiac concentration gradient of each cTnT
form, the possibility remains that degradation occurred after
cTnT was released into the bloodstream. In this regard,
thrombin has been identiﬁed as an extracellular protease
capable of cleaving cTnT at the N-terminal end.18,19 Thrombin is
abundantly generated in patients with MI, and therefore could
have caused extensive cleavage especially inside the CVS,
which is close to the infarcted myocardium.29 Still, we consider
it unlikely that circulating thrombin played a signiﬁcant role
because the relative contribution of each cTnT form remained
stable throughout the coronary circulation. In view of the small
chance of signiﬁcant cTnT proteolysis in the trajectory between
the area of injured myocardium and the blood collected closest
to the injured area, it is assumed that the samples from the CVS
reﬂect normal venous cardiac metabolism, which is also
recognized by others.30–32 Importantly, cleavage at the C-
terminal end of cTnT is also required for the generation of the
smallest cTnT fragments and thus other unidentiﬁed (intracel-
lular) proteases need to be involved in cTnT degradation.
Implications
The data presented in this explorative study have important
implications. Recently, it has been suggested that condition-
speciﬁc cTnT degradation patterns might serve as a proxy for
Figure 4. cTnT composition through gel ﬁltration chromatography in lithium-heparinized (LH) plasma and serum samples of patients 1 and 2 at
the different coronary venous system and peripheral sampling sites. A-T0 indicates peripheral artery sample at baseline; GCV, great cardiac vein
sample; hs-cTnT, high-sensitivity cardiac troponin T; MCV, coronary sinus sample at the ostium of the middle cardiac vein; PLV, coronary sinus
sample near the proximal posterolateral vein; V-T0, peripheral vein sample at baseline; V-T12, peripheral vein sample 12 hours postprocedure;
V-T6, peripheral vein sample 6 hours postprocedure.
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a more speciﬁc hs-cTnT immunoassay.12–14 In patients with
end-stage renal disease and in asymptomatic recreational
runners, who ﬁnished a marathon, only the smallest 15 to
18 kDa cTnT fragments were observed.10,11 In contrast, in our
NSTEMI patients we observed release of larger cTnT forms
(cTn T-I-C complex, free intact 40 kDa cTnT, and 29 kDa cTnT
fragments). In addition, we showed that these forms were
likely to be generated inside the heart. Therefore, they could
be the result of intracellular disease-speciﬁc cTnT cleavage
instead of normal in vivo protein breakdown, or pre-analytical
proteolysis. Consequently, if the observed forms reﬂect a
speciﬁc state of disease, a hs-cTnT immunoassay only
targeting cTnT forms ≥29 kDa may discriminate cTnT release
in the setting of an MI from cTnT release in other (patho)-
physiologies. Noteworthy, given the observed pre-analytically
induced cTn T-I-C complex disintegration and cTnT degrada-
tion in serum, LH plasma should be the preferred blood matrix
for such a next-generation hs-cTnT immunoassay. Additional
blood matrices are approved by the manufacturer (eg, EDTA
plasma), but their potential pre-analytical effects on the cTnT
composition remain to be elucidated.
Another interesting observation was the disappearance
over time of cTn T-I-C complex in our NSTEMI patients. In the
late presenting patient, a markedly lower proportion of cTn T-
I-C complex was observed as compared with the early
presenting patient. The presence of cTn T-I-C complex might
therefore hint toward the “age of the infarction.” This is of
particular interest in patients in whom symptom onset is
uncertain. Given the complete cTn T-I-C complex disintegra-
tion 20 hours after symptom onset, the presence of cTn T-I-
C complex seems indicative of an “early” presentation,
whereas the absence of cTn T-I-C complex may reﬂect a
“late” presentation. Ultimately, the cTn T-I-C complex propor-
tion could provide guidance in the selection of patients who
will beneﬁt the most from an invasive strategy with a
percutaneous coronary intervention. Larger numbers of
patients are needed to investigate the relation between the
cTnT composition and time from infarction to blood draw.
Also, it would be interesting to investigate the cTnT compo-
sition in case of troponin elevation in patients with conditions
other than MI.
Limitations
This work is limited by the fact that only 2 patients were
selected for elaborate cTnT composition analyses. Given the
Figure 5. Western blot analysis of lithium-heparinized (LH) plasma and serum samples of patient 1 and patient 2 at the different coronary
venous system and peripheral sampling sites. A-T0 indicates peripheral artery sample at baseline; cTnT, cardiac troponin T; GCV, great cardiac
vein sample; M, protein standard marker; MCV, coronary sinus sample at the ostium of the middle cardiac vein; N, negative control; P, puriﬁed
intact cTnT positive control; PLV, coronary sinus sample near the proximal posterolateral vein; V-T0, peripheral vein sample at baseline; V-T12,
peripheral vein sample 12 hours postprocedure; V-T6, peripheral vein sample 6 hours postprocedure.
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conceptual nature of our study, the analyses should be
considered as a proof of concept to describe cTnT forms close
to their origin of release, and as such fuel the search for
condition-speciﬁc cTnT degradation patterns. Studying the
cTnT composition with our GFC laboratory setup is a highly
specialized and labor-intensive analysis requiring 1200 hs-
cTnT concentration measurements per patient. The present
GFC setup is currently the most sensitive technology to study
the cTnT composition. Therefore, in our opinion, we provide
one of the most detailed descriptions of cTnT composition in
NSTEMI patients to date, including observations from samples
taken near its site of release. Despite the age of the blood
samples (patients consented in 2006), we previously evalu-
ated that long-time storage at 80°C does not impact the
cTnT composition. Additionally, fresh sample aliquots were
used to prevent freeze–thaw cycles impacting the hs-cTnT
concentration or cTnT composition. Unfortunately, there was
too little posterolateral vein serum material available from
patient 2 for GFC and WB analysis. In addition, our study did
not include patients who presented very early after symptom
onset (<3 hours). In theory, in such a population the cTnT
composition might have been different with cTn T-I-C complex
and intact cTnT as prevailing forms. Finally, hs-cTnT concen-
trations were not sufﬁcient to meet the analytical sensitivity
requirements for mass-spectrometric evaluation. However,
previous work from our group showed that the observed cTnT
fragments on GFC analyses were cTnT-derived degradation
products.8
Conclusion
In conclusion, in this explorative multisite coronary and
peripheral sampling study we demonstrated that the cTnT
composition is dependent on the interval that passed since the
onset of symptoms. This indicates that cTnT is subject to in vivo
degradation. More importantly, we demonstrated that cTnT is
released from the injured myocardium in multiple forms (cTn T-
I-C complex, free intact 40 kDa cTnT, 29 kDa, and 15 to
18 kDa cTnT fragments), which is the ﬁrst in vivo proof of cTnT
degradation within the cardiomyocyte. These new insights
ultimately may provide guidance in the development of a next-
generation hs-cTnT assay with improved speciﬁcity for the
acute phase of MI (Figure 6).
Figure 6. Through multisite sampling in both the coronary venous system (yellow dots1, 2, and 3) and the peripheral circulation, we unraveled
that cardiac troponin T (cTnT) is released from the myocardium as a mixture of cTn T-I-C complex, free intact cTnT, and multiple cTnT fragments
in patients with non–ST-segment–elevation myocardial infarction (MI, star) supporting intracellular degradation. In addition, we observed in vivo
degradation in a time-dependent manner. Based on descriptions of cTnT composition in conditions other than myocardial infarction (eg, end-
stage renal disease, vigorous exercise) current ﬁndings may pave the way towards the development of a new generation hs (high-sensitivity)-
cTnT immunoassay with improved speciﬁcity for myocardial infarction.
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Data S1. 
 
TRAMICI IN- AND EXCLUSION CRITERIA 
 
Inclusion criteria: 
Patients (≥ 18 years) from the Radboud University Medical Center (Radboud UMC) and three 
referring centers were eligible if they presented early after symptom onset, were diagnosed with a 
NSTEMI and had evidence of elevated (i.e. above the 99th percentile upper reference limit from a 
healthy population) and rising cardiac troponin levels based on conventional troponin assays used in 
the respective hospitals. Subsequently, patients were referred for a clinically indicated coronary 
angiography (CAG) in the Radboud UMC. Upon identification of the culprit coronary artery by the 
interventional cardiologist, patients were included and study procedures were started. After 
obtaining oral informed consent prior to the procedure, participants provided written informed 
consent. 
 
Exclusion criteria: 
1) Prior anginal complaints or myocardial infarction in the 3 weeks preceding the qualifying 
episode of chest discomfort in the case of a positive admission troponin concentration; 
2) Indication for treatment with fibrinolysis or urgent PCI at index presentation; 
3) Prior CABG, PCI within last 3 months; 
4) Evidence of other acute or severe cardiac disease (Killip class III or IV) requiring intubation or 
an intra-aortic balloon pump; 
5) Other suspected, potentially life-threatening, non-cardiac disease including pulmonary 
embolism or aortic dissection; 
6) Occurrence of recurrent ischemia at rest after the positive symptom-limited bicycle test and 
before the planned coronary angiography; 
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7) Presence of a pacemaker; 
8) Presence of catheters for hemodynamic monitoring; 
9) Any situation that precludes using the brachial vein as a puncture site, i.e. after surgery of 
the brachial or axillary region; 
10) Severe peripheral arterial disease (Fontaine III and IV); 
11) Severe main stem stenosis (> 50%); 
12) Known congenital heart disease or anomalous coronary anatomy; 
13) Known renal insufficiency (serum creatinine > 150 µmol/L); 
14) Pregnancy; 
15) Systemic infection, hematologic disorder or treatment with an immune suppressive agent; 
treatment with NSAID; treatment with antibiotics. 
16) Any other condition which, in the opinion of the investigator, may pose a significant hazard 
to the subject if he or she is enrolled in the study. 
17) Presence of collateral coronary artery filling at angiography was considered a relative 
exclusion criterion. 
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BLOOD SAMPLING PROCEDURES 
After identification of a culprit lesion by the interventional cardiologist and local team of 
investigators, the coronary venous anatomy was recorded during coronary angiography by filming 
the complete washout of contrast dye. Access to the coronary sinus (CS) was gained by means of a 
right-sided catheterization procedure. For cannulation and blood sampling of the coronary venous 
system (CVS) a Terumo wire (Terumo Europe NV, Leuven, Belgium) and CHAMP multipurpose 
catheter (Medtronic, Santa Rosa, CA, USA) were used, respectively.  
Coronary venous blood samples: after cannulation of the CS, the CHAMP catheter was advanced into 
the great cardiac vein (GCV). This vein primarily drains blood from the anteroseptal walls. 
Consequently, a selective blood sample from this site allows measurement of biomarker 
concentrations in blood that just passed injured (culprit lesion in the left anterior descending (LAD) 
artery) myocardium. Before blood sampling, the position of the catheter was confirmed using 
contrast dye, and then flushed. After sampling, the catheter was pulled back towards the 
posterolateral vein (PLV), were blood from the posterolateral wall enters the CS. Again, position was 
confirmed with contrast dye, and the catheter flushed before sampling. Finally, the catheter was 
pulled back in the CS at the point where the middle cardiac vein merges with the CS. This location 
can be seen as the gathering point of all the blood that ran through the myocardium. Again, position 
of the catheter was confirmed with contrast dye, and the catheter flushed before blood sampling. 
For all blood sample collections, a 30 second waiting period was incorporated between flushing and 
obtaining the sample to give ample time for the washout of the flushing fluid. In addition, because 
some flushing fluid could remain in the sampling catheter, we discarded the first blood sample 
syringe. 
Systemic blood samples: after removal of the catheter from the CVS, systemic blood samples were 
obtained from the femoral venous and arterial sheaths. 
Follow-up blood samples: at 6 and 12 hours post-procedure, additional peripheral venous samples 
were obtained from the antecubital vein. 
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LABORATORY TECHNIQUES 
Biochemical analyses: cTnT concentrations were measured by utilizing the high-sensitivity (hs-)cTnT 
immunoassay (Roche Diagnostics, Basel, Switzerland) with a limit of blank (LoB) at 3 ng/L, limit of 
detection (LoD) at 5 ng/L, 10% coefficient of variation (CV) cutoff at 13 ng/L and a determined 99th 
percentile from a healthy reference population at 14 ng/L. Creatinine concentrations (Roche 
Diagnostics) were determined with a LoD at 5 µmol/L and a 10% CV cutoff at 80 µmol/L.  
 
Gel filtration chromatography (GFC): Separation of the different cTnT forms was performed by GFC 
on the AKTA Prime Plus (GE Healthcare, Chicago, Illinois, United States) equipped with the HiPrep™ 
16/60 Sephacryl™ S-300 HR column (#17-1167-01, GE Healthcare). The column was equilibrated with 
GFC running buffer consisted of 0.26 mol/L NaCI, 2.5 mmol/L CaCl2·2 H2O, 0.02 mol/L Tris, 6 mmol/L 
NaN3 and 1 g/L BSA buffer, pH 7.4 and operated at a flow of 0.5 mL/min. Two columns of identical lot 
numbers were used for the fractionation of all samples. The void volume (V0) of each column was 
assessed using blue dextran and determined to be 42 mL. To investigate circulating cTnT forms in the 
two selected patients 0.25 mL LH plasma or serum was loaded on the GFC column. For each sample 
loaded, 83 fractions of 1 mL were collected and kept on ice until hs-cTnT concentration 
determination (<1 h), and subsequently stored at -80 °C.  
From previous experience, utilizing the identical system and GFC column, retention volumes (VR; 
corrected for V0) for the cTn T-I-C complex, free intact 40 kDa cTnT and its 29 kDa fragment, and 15-
18 kDa cTnT fragments were expected at approximately 21, 30 and 45 mL, respectively. Separation of 
free intact 40 kDa cTnT and its 29 kDa fragment was not achieved with GFC (both ± 30 mL), but 
obtained by Western blotting.  
 
cTnT purification and Western blotting: Purification of cTnT in all patient samples was achieved by 
immunoprecipitation. Ten µg biotinylated M11.7 monoclonal antibody (as kindly provided by Roche 
Diagnostics) was cross-linked to 1 mL M-270 Streptavidin DynaBeads (#65306, Thermo Fisher 
D
ow
nloaded from
 http://ahajournals.org by on October 14, 2019
Scientific, Waltham, Massachusetts, United States). Subsequently, 50 µL beads were incubated with 
200 µL LH plasma or serum for 1 hour at 4 °C. After washing the beads 4 times in phosphate buffered 
saline with 0.1 % (v/v) Tween-20 (#P1379, Merck, Darmstadt, Germany), captured cTnT was eluted in 
25 µL citric acid at pH = 2.5 for 15 min at 56 °C. After adding 6 µL XT Sample Buffer 4x (#1610791, Bio-
Rad, Hercules, California, United States) to 18 µL eluate, samples were loaded on 12 % criterion XT 
(#345-0118, Bio-Rad) precast gels, together with the Precision Plus Protein™ molecular weight 
marker (#1610373, Bio-Rad). After stacking the samples for 15 min at 100 V, cTnT proteoforms were 
separated for 45 min at 200 V. The gels were subsequently blotted on 0.45 µm nitrocellulose 
membranes (#1620115, Bio-Rad) for 1 hour at 100 V. Antibody application to the nitrocellulose 
membrane was performed using the SNAP i.d.® 2.0 Protein Detection System (Merck). The primary 
detector antibody used was the anti-cTnT M7 monoclonal antibody (as kindly provided by Roche 
Diagnostics) and horseradish peroxidase-labeled goat anti-mouse polyclonal antibody served as the 
secondary detector antibody. Finally, blots were incubated with in SuperSignal West Femto 
Maximum Sensitivity Substrate (#34096, Thermo Scientific) and bands were detected using the 
ChemiDoc XRS system (Bio-Rad) and Quantity One software (Bio-Rad, version 4.6.6.). 
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Figure S1. CORONARY VENOUS SYSTEM BLOOD SAMPLE COLLECTION. 
 
 
Schematic view of the blood samples collected from the coronary venous system. 1 = great cardiac 
vein sample; 2 = coronary sinus sample at the ostium of the most proximal posterolateral vein; 3 = 
coronary sinus sample at the ostium of the middle cardiac vein; arrows = blood flow. Adapted from 
Khan et al1 with permission. Copyright ©2009, Oxford University Press. D
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Figure S2. GFC ELUTION PROFILE. 
 
 
Schematic view of the different cTnT forms and their expected location on the GFC elution profile. 
The following forms of cTnT are reported in this manuscript:  
• Peak at ± 21 mL: ternary cardiac troponin T-I-C complex 
• Peak at ± 29-32 mL: free intact 40 kDa cTnT and/or 29 kDa cTnT fragments 
• Peak at ± 41-44 mL: 15-18 kDa cTnT fragments 
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Figure S3. ANGIOGRAMS PATIENT 1 & 2. 
 
 
 
Diagnostic coronary angiogram of patient 1 and patient 2. Red circle = location of the stenosis. 
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Figure S4. HS-CTNT CONCENTRATION REGRESSION ANALYSIS BETWEEN LITHIUM-HEPARINIZED 
PLASMA AND SERUM. 
   
 
Passing-Bablok regression analysis comparing lithium-heparinized (LH) plasma and serum hs-cTnT 
concentrations (ng/L) measured in duplicate in all coronary venous system and peripheral samples of 
the two patients selected for cTnT composition analysis (n=14). 
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Figure S5. GFC ELUTION PROFILE PATIENT 1. 
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Gel filtration chromatography elution profiles of all lithium-heparinized (LH) plasma (A-G) and serum 
(H-N) samples from patient 1. A = great cardiac vein LH plasma sample; B = coronary sinus LH plasma 
sample near the proximal posterolateral vein; C = coronary sinus LH plasma sample at the ostium of 
the middle cardiac vein; D = peripheral artery LH plasma sample at baseline; E = peripheral vein LH 
plasma sample at baseline; F = peripheral vein LH plasma sample 6 hours post-procedure; G = 
peripheral vein LH plasma sample 12 hours post-procedure; H = great cardiac vein serum sample; I = 
coronary sinus serum sample near the proximal posterolateral vein; J = coronary sinus serum sample 
at the ostium of the middle cardiac vein; K = peripheral artery serum sample at baseline; L = 
peripheral vein serum sample at baseline; M = peripheral vein serum sample 6 hours post-procedure; 
N = peripheral vein serum sample 12 hours post-procedure. 
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Figure S6. GFC ELUTION PROFILE PATIENT 2. 
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Gel filtration chromatography elution profiles of all lithium-heparinized (LH) plasma (A-G) and serum 
(H-M) samples from patient 2. A = great cardiac vein LH plasma sample; B = coronary sinus LH plasma 
sample near the proximal posterolateral vein; C = coronary sinus LH plasma sample at the ostium of 
the middle cardiac vein; D = peripheral artery LH plasma sample at baseline; E = peripheral vein LH 
plasma sample at baseline; F = peripheral vein LH plasma sample 6 hours post-procedure; G = 
peripheral vein LH plasma sample 12 hours post-procedure; H = great cardiac vein serum sample; I = 
coronary sinus serum sample at the ostium of the middle cardiac vein; J = peripheral artery serum 
sample at baseline; K = peripheral vein serum sample at baseline; L = peripheral vein serum sample 6 
hours post-procedure; M = peripheral vein serum sample 12 hours post-procedure. 
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